| Status: In progress | |
Treatment of PAH in adolescents and children (aged 8 to less than 18 years) of WHO Functional Class (FC) II to III including use in combination treatment. Efficacy has been shown in IPAH, familial, corrected congenital and in PAH associated with connective tissue disease. |
|
Medicine details |
|
| Medicine name | ambrisentan (Volibris®) |
| Formulation | 2.5 mg, 5 mg, 10 mg film-coated tablet |
| Reference number | 4819 |
| Indication | As above |
| Company | GlaxoSmithKline UK |
| BNF chapter | Cardiovascular system |
| Submission type | Licence extension for paediatric use |
| Status | In progress |
| Advice number | TBC |
| AWMSG meeting date | 18/10/2022 |
| Date of issue | TBC |